852949-71-4

Upstream product

• 848442-44-4 trifluoromethanesulfonic acid 4-(3-isopropyl-4-methoxymethoxybenzyl)-3,5-dimethylphenyl ester 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 

Downstream Products

• 852949-72-5 3,5-dimethyl-4-(4'-methoxymethoxy-3'-iso-propylbenzyl)benzoic acid 
• 1282618-41-0 cis-(S)-4-[4-[4-(3-chlorophenyl)-2-oxo-2-λ5-[1,3,2]dioxaphosphinan-2-yloxymethyl]-2,6-dimethyl-benzyl]-2-isopropylphenol 
• 848442-55-7 3,5-dimethyl-4-(3-isopropyl-4-hydroxybenzyl)benzyl alcohol 
• 877220-33-2 [3,5-Dimethyl-4-(3'-isopropyl-4'-methoxymethoxy-benzyl)-phenyl]-methanol 

Relevant academic research and scientific papers

NOVEL SULFONIC ACID-CONTAINING THYROMIMETICS, AND METHODS FOR THEIR USE

The present invention relates to sulfonic acid containing compounds of formula IB, in which G, R1, R3 and T are as defined in the claims, that bind to thyroid receptors in the liver. Activation of these receptors results in modulation of gene expression of genes regulated by thyroid hormones. The compounds can be used to treat diseases and disorders including metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome X and diabetes.

Novel Phosphinic Acid-Containing Thyromimetics

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs

Phosphonic acid (PA) thyroid hormone receptor (TR) agonists were synthesized to exploit the poor distribution of PA-based drugs to extrahepatic tissues and thereby to improve the therapeutic index. Nine PAs showed excellent TR binding affinities (TRβ

NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS

The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.